ChiCTR-ONC-13003015
正在进行
/
/
/
2013-01-22
/
/
Atrial Fibrillation
Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation
Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation
To assess the effect and safety of Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation.
连续入组
Ⅳ期
NA
/
SK Yee Funding, CUHK
/
80
/
2013-02-28
1990-01-01
/
1. Adults above the age of 18; 2. Non-valvular AF, at high risk of stroke and who have experienced serious bleeding events or repeated nuisance bleed events whilst on warfarin or NOACs; 3. Non-valvular AF, at high risk of stroke and who are intolerant of, has significant side effect, or decline to take warfarin or NOACs; 4. Non-valvular AF, at high risk of stroke and who are poorly compliant with warfarin (Time in therapeutic range <60%) or NOACs; 5. Non-valvular AF, at high risk of stroke and who are at high risk of bleeding as evidenced by a high HAS-BLED score.；
请登录查看1. Inability to take Aspirin and Clopidogrel; 2. Inability to give informed consent; 3. Patients unlikely to benefit from the therapy due to a short life expectancy; 4. NYHA 4; 5. LVEF <30%; 6. Moderate-to-severe or worse mitral or aortic valvular regurgitation or stenosis; 7. Suspected or known intracardiac thrombus; 8. Symptomatic carotid disease.；
请登录查看SK Yee Funding, CUHK
/
英百瑞生物2025-12-05
艾力斯医药科技2025-12-05
神曦生物NeuExcell2025-12-05
科望医药2025-12-05
宠药生态圈2025-12-05
丁香园 Insight 数据库2025-12-05
佰傲谷BioValley2025-12-05
药精通Bio2025-12-05
医药观澜2025-12-05
贝达药业2025-12-05
400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
